Form 4: Arcus Biosciences Director Acquires Stock Options in Recent Transaction

Arcus Biosciences director Antoni Ribas acquired 5,000 stock options and disposed of 30,350 common shares in a recent transaction.

Summary

• Director Antoni Ribas of Arcus Biosciences, Inc. engaged in a transaction involving the company's stock.
• Ribas acquired 5,000 stock options with an exercise price of $13.33, exercisable in 24 equal monthly installments starting after January 1, 2025, and expiring on January 22, 2035.
• The director also disposed of 30,350 common shares and holds 8,553 shares indirectly through a trust.
• The transaction was reported on January 27, 2025, with the earliest transaction date being January 23, 2025.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a director's stock transactions. It doesn't indicate any positive or negative sentiment, but rather a standard reporting requirement.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the transactions of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The reported transactions are typical for directors who receive stock options as part of their compensation.
• The exercise price of $13.33 is specific to the company's stock and its valuation at the time of the grant.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The stock option grant aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, director, Arcus Biosciences, RCUS, equity securities